Status:

ENROLLING_BY_INVITATION

Mid-frontal Delta/Theta and Cognitive Control

Lead Sponsor:

Nandakumar Narayanan

Collaborating Sponsors:

National Institute of Neurological Disorders and Stroke (NINDS)

Conditions:

Parkinson&Amp;Amp;#39;s Disease (PD)

Eligibility:

All Genders

18-99 years

Phase:

NA

Brief Summary

Abstract Cognitive symptoms of Parkinson's disease (PD) include deficits in attention, working memory, and reasoning. These deficits affect up to 80% of PD patients and lead to mild cognitive impairme...

Detailed Description

Up to 80% of patients with Parkinson's disease (PD) will suffer from cognitive symptoms, including impaired attention, planning, reasoning, and working memory as well as hallucinations, visuospatial d...

Eligibility Criteria

Inclusion

  • We will study individuals with idiopathic mild-moderate Parkinson's Disease. Diagnosis will be confirmed by Dr. Narayanan - a neurologist.
  • Inclusion criteria:
  • GROUP 1: Parkinson's disease without cognitive impairment
  • Parkinson's disease, with MOCA \> 26
  • under stable PD medication
  • able to walk independently, make their own decisions
  • age range = 18 - 89 years old
  • GROUP 2: Parkinson's disease with mild cognitive impairment
  • Parkinson's disease, with MOCA 23-26
  • under stable PD medication
  • able to walk independently, make their own decisions
  • age range = 18 - 89 years old
  • GROUP 3: Parkinson's disease with dementia
  • Parkinson's disease, with MOCA \< 23
  • under stable PD medication
  • Make their own decisions
  • age range = 18 - 89 years old
  • GROUP 4: Parkinson's disease with STN-DBS 1) Parkinson's disease with functioning bilateral STN-DBS electrodes 2) under stable PD medication 3) able to walk independently, make their own decisions 4) age range = 18 - 89 years old 5) THIS GROUP WILL NOT UNDERGO TMS
  • GROUP 5: Parkinson's disease without DBS and with no seizure history for EEG-TMS study
  • Parkinson's disease with MOCA 23-30
  • under stable PD medication
  • able to walk independently, make their own decisions
  • age range = 18 - 89 years old
  • GROUP 6: Essential tremor with VIM-DBS
  • 1\) Essential tremor with functioning bilateral VIM-DBS electrodes 2) able to walk independently, make their own decisions 3) age range = 18 - 89 years old 4) THIS GROUP WILL NOT UNDERGO TMS
  • GROUP 7: Parkinson's disease without DBS and with no seizure history for EEG-HD-tACS study 1) Parkinson's disease with MOCA 23-30 2) under stable PD medication 3) able to walk independently, make their own decisions 4) age range = 18 - 89 years old
  • Exclusion criteria:
  • Patients with dementia with Lewy Bodies and Alzheimer's disease, drug-induced parkinsonism, Parkinson's-plus, on investigational drugs, with hearing loss will be excluded, or with color-blindness will be excluded. Subjects with a history of neuropsychiatric disorders, like Schizophrenia or Depression will be also be excluded.
  • For the TMS sub-study, PD patients with DBS leads will be excluded and any subject with a seizure disorder will also be excluded. For the HD-tACS sub-study, PD patients with DBS leads will be excluded and any subject with a seizure disorder will also be excluded.
  • Control Group: patients with Alzheimer's Disease (AD) and dementia with Lewy Bodies (DLB) A group of patients with AD and DLB will be recruited for the cognitive tasks to compare data with PD. Since AD is non-dopamine deficiency disease so they can serve as another control group for the study.
  • Inclusion criteria:
  • 1\) age range = 18 - 89 years old (will have to match with the age of subjects with Parkinson's Disease)
  • Exclusion criteria:
  • 1\) with any neurological disorders, including epilepsy
  • Control Group: patients with mTBI A group of patients with mTBI will be recruited for the cognitive tasks to compare data with PD.
  • Inclusion criteria:
  • 1\) age range = 18 - 89 years old (will have to match with the age of subjects with Parkinson's Disease)
  • Exclusion criteria:
  • Control Group: patients with 16pDel Autism A group of patients with 16pDel Autism will be recruited for the cognitive tasks to compare data with PD.
  • Inclusion criteria:
  • 1\) age range = 18 - 89 years old (will have to match with the age of subjects with Parkinson's Disease)
  • Exclusion criteria:
  • Control Group: patients with Brain Lesions A group of patients with Brain Lesions will be recruited for the cognitive tasks to compare data with PD.
  • Inclusion criteria:
  • 1\) age range = 18 - 89 years old (will have to match with the age of subjects with Parkinson's Disease)
  • Exclusion criteria:
  • Control Group: Older Normal Subjects A group of older healthy individuals will be matched with subjects with Parkinson's disease in terms of age, sex, and years of education. We will also recruit a small group of older healthy individuals specifically to pilot new behavioral tasks.
  • Inclusion criteria:
  • 1\) age range = 35 - 99 years old (most of this group will have to match with the age of subjects with Parkinson's Disease. One subset from this group (N = 40) will be independent from the demographics of the subjects with Parkinson's Disease, so they can have a wider age range).
  • Exclusion criteria:
  • 1\) with any neurological disorders, including epilepsy
  • Control Group: Older Subjects with Mood Disorders A group of older individuals with Mood Disorders will be recruited to perform cognitive tasks to compare data with both PD with Mood Disorders and PD without Mood Disorders.
  • Inclusion criteria:
  • 1\) age range = 18 - 89 years old (will have to match with the age of subjects with Parkinson's Disease)
  • Exclusion criteria:
  • 1\) with any neurological disorders, including epilepsy
  • Control group: Healthy young and middle-aged adults
  • A group of healthy young and middle-aged adults without Parkinson's disease or other neurological issues.
  • 1\) age range = 18-60 years old
  • Exclusion criteria: 1) any neurological disorders, including epilepsy
  • Control subjects' mothers
  • \- The group of mothers of the healthy young adult control subjects.

Exclusion

    Key Trial Info

    Start Date :

    September 25 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 31 2029

    Estimated Enrollment :

    635 Patients enrolled

    Trial Details

    Trial ID

    NCT06984757

    Start Date

    September 25 2017

    End Date

    December 31 2029

    Last Update

    May 22 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Iowa

    Iowa City, Iowa, United States, 52242

    Mid-frontal Delta/Theta and Cognitive Control | DecenTrialz